Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism ‐related factors in patients with type‐2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Kyu Yon1g Cho,
Akinobu Nakamura,
Kazuno Omori,
Takahiro Takase,
Aika Miya,
Naoki Manda,
Yoshio Kurihara,
Shin Aoki,
Tatsuya Atsumi,
Hideaki Miyoshi Source Type: research
More News: Actos | Dapagliflozin | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Forxiga | Obesity | SGLT2 Inhibitors